34 related articles for article (PubMed ID: 11374862)
1. EBAG9 inducing hyporesponsiveness of T cells promotes tumor growth and metastasis in 4T1 murine mammary carcinoma.
Hong X; Liu Y; Hu G; Zhao D; Shen J; Shen F; Cao X; Wang Q
Cancer Sci; 2009 May; 100(5):961-9. PubMed ID: 19445026
[TBL] [Abstract][Full Text] [Related]
2. EBAG9 silencing exerts an immune checkpoint function without aggravating adverse effects.
Wirges A; Bunse M; Joedicke JJ; Blanc E; Gudipati V; Moles MW; Shiku H; Beule D; Huppa JB; Höpken UE; Rehm A
Mol Ther; 2022 Nov; 30(11):3358-3378. PubMed ID: 35821635
[TBL] [Abstract][Full Text] [Related]
3. Extracellular vesicle-mediated EBAG9 transfer from cancer cells to tumor microenvironment promotes immune escape and tumor progression.
Miyazaki T; Ikeda K; Sato W; Horie-Inoue K; Inoue S
Oncogenesis; 2018 Jan; 7(1):7. PubMed ID: 29362448
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of the tumor-associated antigen AAA-TOB3.
Schaffrik M; Mack B; Matthias C; Rauch J; Gires O
Cell Mol Life Sci; 2006 Sep; 63(18):2162-74. PubMed ID: 16909202
[TBL] [Abstract][Full Text] [Related]
5. Molecular Changes on Maternal-Fetal Interface in Placental Abruption-A Systematic Review.
Bączkowska M; Zgliczyńska M; Faryna J; Przytuła E; Nowakowski B; Ciebiera M
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205566
[TBL] [Abstract][Full Text] [Related]
6. EBAG9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of T lymphocytes.
Miyazaki T; Ikeda K; Horie-Inoue K; Kondo T; Takahashi S; Inoue S
Oncogenesis; 2014 Nov; 3(11):e126. PubMed ID: 25365482
[TBL] [Abstract][Full Text] [Related]
7. Med1 plays a critical role in the development of tamoxifen resistance.
Nagalingam A; Tighiouart M; Ryden L; Joseph L; Landberg G; Saxena NK; Sharma D
Carcinogenesis; 2012 Apr; 33(4):918-30. PubMed ID: 22345290
[TBL] [Abstract][Full Text] [Related]
8. The tumor-associated antigen EBAG9 negatively regulates the cytolytic capacity of mouse CD8+ T cells.
Rüder C; Höpken UE; Wolf J; Mittrücker HW; Engels B; Erdmann B; Wollenzin S; Uckert W; Dörken B; Rehm A
J Clin Invest; 2009 Aug; 119(8):2184-203. PubMed ID: 19620783
[TBL] [Abstract][Full Text] [Related]
9. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.
Ford CE; Ekström EJ; Andersson T
Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3919-24. PubMed ID: 19237581
[TBL] [Abstract][Full Text] [Related]
10. The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse.
Dutsch-Wicherek M; Tomaszewska R; Lazar A; Wicherek L; Skladzien J
BMC Cancer; 2009 Jan; 9():35. PubMed ID: 19175908
[TBL] [Abstract][Full Text] [Related]
11. Switching of chromatin-remodelling complexes for oestrogen receptor-alpha.
Okada M; Takezawa S; Mezaki Y; Yamaoka I; Takada I; Kitagawa H; Kato S
EMBO Rep; 2008 Jun; 9(6):563-8. PubMed ID: 18451880
[TBL] [Abstract][Full Text] [Related]
12. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
Sharma D; Saxena NK; Davidson NE; Vertino PM
Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
[TBL] [Abstract][Full Text] [Related]
13. The analysis of RCAS1 and DFF-45 expression in nasal polyps with respect to immune cells infiltration.
Dutsch-Wicherek M; Tomaszewska R; Strek P; Wicherek L; Skladzien J
BMC Immunol; 2006 Mar; 7():4. PubMed ID: 16551346
[TBL] [Abstract][Full Text] [Related]
14. The placental RCAS1 expression during stillbirth.
Wicherek L; Klimek M; Czekierdowski A; Popiela TJ; Galazka K; Tetlak T; Gilowski A; Dutsch-Wicherek M
Reprod Biol Endocrinol; 2005 Jun; 3():24. PubMed ID: 15963226
[TBL] [Abstract][Full Text] [Related]
15. Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker.
Reimer TA; Anagnostopoulos I; Erdmann B; Lehmann I; Stein H; Daniel P; Dörken B; Rehm A
BMC Cancer; 2005 May; 5():47. PubMed ID: 15904507
[TBL] [Abstract][Full Text] [Related]
16. EBAG9 adds a new layer of control on large dense-core vesicle exocytosis via interaction with Snapin.
Rüder C; Reimer T; Delgado-Martinez I; Hermosilla R; Engelsberg A; Nehring R; Dörken B; Rehm A
Mol Biol Cell; 2005 Mar; 16(3):1245-57. PubMed ID: 15635093
[TBL] [Abstract][Full Text] [Related]
17. Differential gene regulation by the SRC family of coactivators.
Zhang H; Yi X; Sun X; Yin N; Shi B; Wu H; Wang D; Wu G; Shang Y
Genes Dev; 2004 Jul; 18(14):1753-65. PubMed ID: 15256502
[TBL] [Abstract][Full Text] [Related]
18. Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.
Akahira JI; Aoki M; Suzuki T; Moriya T; Niikura H; Ito K; Inoue S; Okamura K; Sasano H; Yaegashi N
Br J Cancer; 2004 Jun; 90(11):2197-202. PubMed ID: 15164121
[TBL] [Abstract][Full Text] [Related]
19. Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen.
Tsuchiya F; Ikeda K; Tsutsumi O; Hiroi H; Momoeda M; Taketani Y; Muramatsu M; Inoue S
Biochem Biophys Res Commun; 2001 Jun; 284(1):2-10. PubMed ID: 11374862
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
